Kyverna Therapeutics Overview
Valuation check: KYTX's P/E ratio is -2.32, below the sector sector average of 24.91.
Get informed when a big investor buys or sells
+ Follow-2.32
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Kyverna Therapeutics posts a P/E ratio of -2.32. That is below the sector sector average of 24.91. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a P/E ratio near 24.91 is typical. Kyverna Therapeutics's -2.32 is lower that level. That is roughly 109.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Kyverna Therapeutics's P/E ratio of -2.32 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.
Context for KYTX's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 24.91), and (3) consistency with growth and profitability. This page covers the first two; Kyverna Therapeutics's other metric pages and overview cover the third.
